Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure.

Stephane Heymans,Aernout Luttun,Dieter Nuyens,Gregor Theilmeier,Eejm Creemers,Lieve Moons,G D Dyspersin,Jpm Cleutjens,M Shipley,A Angellilo,Marcel Levi,O Nübe,Andrew H. Baker,Eli Keshet,Florea Lupu,Jean-Marc Herbert,Jos F.M. Smits,Steve Shapiro,Myriam Baes,Marcel Borgers,Desire Collen,Mat J.A.P. Daemen,Peter Carmeliet

Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure.

1999

Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure

Keywords:

Immunology
Plasminogen activator inhibitor-1
Heart Rupture
Cardiac Rupture
Plasminogen Inactivators
Plasminogen activator
Medicine
Matrix metalloproteinase
Vascular endothelial growth factor
Therapeutic angiogenesis
Myocardial infarction
Ischemia
Contractility

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

765

Citations